Aduro Biotech (Aduro Biotech) EV-to-Revenue : 8.48 (As of May. 12, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Aduro Biotech EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aduro Biotech's enterprise value is $236.93 Mil. Aduro Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2020 was $27.96 Mil. Therefore, Aduro Biotech's EV-to-Revenue for today is 8.48.

The historical rank and industry rank for Aduro Biotech's EV-to-Revenue or its related term are showing as below:

ADRO's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.37
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-12), Aduro Biotech's stock price is $14.60. Aduro Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 was $1.73. Therefore, Aduro Biotech's PS Ratio for today is 8.42.

Aduro Biotech EV-to-Revenue Historical Data

The historical data trend for Aduro Biotech's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aduro Biotech EV-to-Revenue Chart

Aduro Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EV-to-Revenue

Get a 7-Day Free Trial

18.82

8.42

14.90

-3.74

-4.92

Aduro Biotech Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
EV-to-Revenue	Get a 7-Day Free Trial															-6.42	-6.87	-4.92	1.89	1.74

Competitive Comparison of Aduro Biotech's EV-to-Revenue

For the Biotechnology subindustry, Aduro Biotech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aduro Biotech's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aduro Biotech's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aduro Biotech's EV-to-Revenue falls into.

Aduro Biotech EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aduro Biotech's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	236.930	/	27.956
	=	8.48

Aduro Biotech's current Enterprise Value is $236.93 Mil.
Aduro Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.96 Mil.

Aduro Biotech (NAS:ADRO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aduro Biotech's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	14.60	/	1.733
	=	8.42

Aduro Biotech's share price for today is $14.60.
Aduro Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.73.

Aduro Biotech EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aduro Biotech's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aduro Biotech (Aduro Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aduro Biotech Inc (NAS:ADRO) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

740 Heinz Avenue, Berkeley, CA, USA, 94710

Website

https://www.aduro.com

Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy.

Executives

Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
William Mariner Greenman	director	C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Ross Haghighat	director	C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Dolca Thomas	director	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Tom Frohlich	officer: Chief Business Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Eric Dobmeier	director, officer: President, CEO	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Davis Jerel	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I Parallel, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Vii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Andrew James King	officer: Head of Renal Discovery	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Alan Glicklich	officer: Chief Medical Officer	C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Celeste Ferber	officer: SVP, GC and Secretary	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Blaine Templeman	officer: Chief Legal Officer	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710